Anti-prion activity found in beetle grub hemolymph of Trypoxylus dichotomus septentrionalis  by Hamanaka, Taichi et al.
Biochemistry and Biophysics Reports 3 (2015) 32–37Contents lists available at ScienceDirectBiochemistry and Biophysics Reportshttp://d
2405-58
Abbre
sistant a
n Corr
E-m
1 La
2-1 Hirojournal homepage: www.elsevier.com/locate/bbrepAnti-prion activity found in beetle grub hemolymph of Trypoxylus
dichotomus septentrionalis
Taichi Hamanaka, Keiko Nishizawa, Yuji Sakasegawa, Hiroshi Kurahashi 1, Ayumi Oguma,
Kenta Teruya, Katsumi Doh-ura n
Department of Neurochemistry, Tohoku University Graduate School of Medicine, 2-1 Seiryocho, Sendai 980-8575, Japana r t i c l e i n f o
Article history:
Received 20 May 2015
Received in revised form
17 June 2015
Accepted 14 July 2015
Available online 17 July 2015
Keywords:
Maillard reaction product
Prion
Insect hemolymph
Strain dependency
Advanced glycation end product
Aminoguanidinex.doi.org/10.1016/j.bbrep.2015.07.009
08/& 2015 The Authors. Published by Elsevier
viations: PrP, prion protein; PrPc, normal cell
bnormal PrP; AGE, advanced glycation end p
esponding author. Fax: þ81 22 717 7656.
ail address: doh-ura@med.tohoku.ac.jp (K. Do
boratory for Protein Conformation Diseases, R
sawa, Wako, Saitama 351-0198, Japan.a b s t r a c t
No remedies for prion disease have been established, and the conversion of normal to abnormal prion
protein, a key event in prion disease, is still unclear. Here we found that substances in beetle grub he-
molymph, after they were browned by aging for a month or heating for hours, reduced abnormal prion
protein (PrP) levels in RML prion-infected cells. Active anti-prion components in the hemolymph were
resistant to protease treatment and had molecular weights larger than 100 kDa. Aminoguanidine
treatment of the hemolymph abolished its anti-prion activity, suggesting that Maillard reaction products
are enrolled in the activity against the RML prion. However, levels of abnormal PrP in RML prion-infected
cells were not decreased by incubation with the Maillard reaction products formed by amino acids or
bovine serum albumin. The anti-prion components in the hemolymph modiﬁed neither cellular or cell-
surface PrP levels nor lipid raft or autophagosome levels. The anti-prion activity was not observed in cells
infected with 22 L prion or Fukuoka-1 prion, suggesting the anti-prion action is prion strain-dependent.
Although the active components of the hemolymph need to be further evaluated, the present ﬁndings
imply that certain speciﬁc chemical structures in the hemolymph, but not chemical structures common
to all Maillard reaction products, are involved in RML prion formation or turnover, without modifying
normal PrP expression. The anti-prion components in the hemolymph are a new tool for elucidating
strain-dependent prion biology.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prion diseases, also called transmissible spongiform en-
cephalopathies, are progressive, fatal neurodegenerative illness.
They include Creutzfeldt-Jakob disease in humans and scrapie,
bovine spongiform encephalopathy, and chronic wasting disease
in animals. These diseases are characterized by the accumulation
of abnormal prion protein (abnormal PrP), which is a main com-
ponent of the pathogen that is derived from the normal prion
protein (PrPc) through a conformational transformation [1]. Ab-
normal PrP molecules form insoluble protein polymers, which
have protease-resistant cores (PrPres). Both the conversion of PrPc
to abnormal PrP and the turnover of abnormal PrP are key events
in prion diseases but are still unclear.
As for remedies for these diseases, dozens of compounds orB.V. This is an open access article u
ular PrP; PrPres, protease-re-
roduct
h-ura).
IKEN Brain Science Institute,substances have been reported to either inhibit prion formation in
prion-infected culture cells or to prolong the incubation period in
prion-infected animals [2–4]. Some remedies are effective in a
prion-strain dependent fashion [5–8], but the mechanism under-
lying prion strain-dependent efﬁcacy remains unclear. Although a
few anti-prion compounds have been tested in clinical trials
against human prion diseases, no sufﬁciently beneﬁcial effects
have ever been reported [9–13].
To obtain clues for the development of remedies as well as to
explore the mechanism of the enigmatic PrP conversion, we
searched for compounds or substances that modify abnormal PrP
formation in prion-infected cells. In earlier studies [14,15], med-
icinal compounds or natural products approved by the United
States Food and Drug Administration had been extensively
screened for anti-prion activity. Therefore, we focused on un-
touched materials obtained from natural sources. We had pre-
viously reported anti-prion substances extracted from natural
sources, including fucoidan and protein-bound polysaccharide K
[16,17]. Insects are under-cultivated natural resources, which exist
abundantly in both number and variety. It may be possible to
discover new insect-derived substances that are useful either for
exploring the PrP conversion mechanism, or for developing thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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viral, and antimicrobial compounds are found in insect extracts
[18–21].
Here we examined insect larva-derived hemolymph, using
prion-infected cells. We found that beetle grub hemolymph in-
hibited abnormal PrP formation in prion-infected cells when the
hemolymph was browned by aging or heating. We then studied
the mechanism by which the browned hemolymph enacted its
anti-prion properties. The Maillard reaction products, also called
advanced glycation end products (AGEs), in the browned hemo-
lymph were suggested to contain the active, anti-prion compo-
nents. These substances are a new type of probe for identifying the
prion strain-dependent formation of abnormal PrP.2. Materials and methods
2.1. Samples and reagents
We obtained grubs of the Japanese horned beetle, Trypoxylus
dichotomus septentrionalis, at the third instar larval stage, from a
local insect shop. Hemolymph from these grubs was obtained as
previously described [22,23] with minor modiﬁcation. Brieﬂy,
phosphate buffer saline (PBS, 100 μL) was injected into the body of
grubs, and the grubs were reared in leaf mold for 5 h. After surface
sterilization and anesthesia on an ice pack, bleeding was done
through the amputated prologs. Hemolymph was collected into
tubes on ice and immediately heated at 95 °C for 5 min. The he-
molymph ﬂuids were subsequently centrifuged at 20,000 g for
10 min at 4 °C. The supernatant from this step was the source of
the hemolymph samples used in the study. The hemolymph
samples were stored at 80 °C, after addition of 20 μg/mL apro-
tinin (Roche, Penzberg, Germany), until use.
Aminoguanidine, glucose, amino acids, and bovine serum al-
bumin (BSA) were purchased from Wako Pure Chemical Industries
(Osaka, Japan). Maillard reaction products of amino acids or BSA
were obtained by incubating 25 mg/mL amino acid or BSA with
125 mg/mL glucose in water at 70 °C for 17 h. Inhibition of the
Maillard reaction was performed by the addition of 230 mM
aminoguanidine into the reaction solution.2.2. Analysis of PrP and other factors
We used mouse neuroblastoma N2a cells as well as three types
of N2a-derived cells infected with distinct prion strains: ScN2a
cells infected with the RML prion, N167 cells infected with the 22 L
prion, and F3 cells infected with the Fukuoka-1 prion. Cells were
treated for three days with test materials as previously described
[6,7,24]. Cell lysates were prepared using lysis buffer (0.5% sodium
deoxycholate, 0.5% Nonidet P-40, PBS, pH 7.4). The amounts of
PrPres, PrPc, β-actin, and autophagosomal protein LC3 in the cell
lysates were determined using an immunoblotting procedure with
a speciﬁc antibody for each protein, as previously described [25].
Flow cytometry was performed to determine the level of cell-
surface PrPc or lipid raft microdomains, in N2a cells, using anti-PrP
monoclonal antibody or ﬂuorescence-conjugated cholera toxin B,
respectively, as described previously [25]. Maillard reaction pro-
ducts were assayed by detecting N(6)-carboxymethyl lysine with
an immunoblotting procedure using 6D12 monoclonal antibody
(1:200; Trans Genic Inc., Kumamoto, Japan) [26].3. Results
3.1. Anti-prion activity of beetle grub hemolymph
We examined whether beetle grub hemolymph of Trypoxylus
dichotomus septentrionalis has anti-prion activity in RML prion-
infected cells. Cells were incubated with the culture medium
containing the hemolymph samples for three days. PrPres levels
were subsequently assayed by immunoblotting. Beetle grub he-
molymph samples were transparent immediately after collection
and heat inactivation, but they gradually changed to a tan color
while stored at 4 °C. The non-aged hemolymph samples did not
inhibit the formation of abnormal PrP in ScN2a cells. However, the
hemolymph samples that had become brown after storage for
1 month at 4 °C inhibited the formation of abnormal PrP in ScN2a
cells. The anti-prion activity was never observed in hemolymph
samples that had been stored for 2 months at 4 °C (Fig. 1A). These
results indicate that beetle grub hemolymph samples contain anti-
prion activity that was gained during aging for one month at 4 °C,
but was lost during an additional month of storage. To shorten the
aging period, the hemolymph samples were heated at 37 °C or
70 °C for 17 h. These heat treatments caused the hemolymph
samples to turn brown and to inhibit the formation of abnormal
PrP in ScN2a cells (Fig. 1B). These results suggest that temperature
is one of the factors that facilitate the production of anti-prion
components in hemolymph samples. Anti-prion activity was ob-
served in hemolymph samples heated at 70 °C for only 3 h; the
anti-prion activity was coincident with the formation of brown
color in the hemolymph samples (Fig. 1C). The anti-prion activity
was maintained in samples treated with protease (Fig. 1D). The
molecular mass of the anti-prion components in the hemolymph
samples was examined by using centrifugal ultraﬁltration devices.
The anti-prion components were found in the retentate of a ﬁlter
with a 100 kDa cut-off; the anti-prion activity was not observed in
the ﬁltrates of any of the four types of ﬁlters (Fig. 1E).
3.2. Characterization of anti-prion components in beetle grub
hemolymph
All the ﬁndings described above imply the involvement of the
Maillard reaction in the production of active anti-prion compo-
nents in the hemolymph samples. Therefore, we examined whe-
ther the Maillard reaction inhibitor aminoguanidine abolished the
anti-prion activity of the hemolymph samples, by heating a mix-
ture of hemolymph and aminoguanidine at 70 °C for 17 h and
subsequently adding the mixture to ScN2a cells. The presence of
Maillard reaction products was conﬁrmed by immunoblotting
with 6D12 monoclonal antibody, which speciﬁcally detects N(6)-
carboxymethyl lysine in Maillard reaction products. As shown in
Fig. 2A, no N(6)-carboxymethyl lysine signals were detected in
hemolymph samples prepared in the presence of aminoguanidine.
Coincidently, anti-prion activity was abolished in hemolymph
samples prepared in the presence of aminoguanidine (Fig. 2B). The
results indicate that the Maillard reaction process is necessary for
the production of anti-prion components in hemolymph samples.
Meanwhile, we examined whether other Maillard reaction
products exert anti-prion activity in ScN2a cells. We investigated
Maillard reaction products prepared by incubation of amino acids
or BSA with glucose at 70 °C for 17 h. The results demonstrate that
the levels of abnormal PrP formed in ScN2a cells were not reduced
by any of these samples. Rather, the levels of abnormal PrP in-
creased obviously in ScN2a cells treated with samples prepared
from lysine or a lysine-containing amino acid mixture (Fig. 2C,
Glucose (þ)). This increase in PrPres levels was abolished when
the samples were prepared in the presence of aminoguanidine
(Fig. 2C, Glucose (þ) and AG (þ)). These results suggest that
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Fig. 1. Anti-prion activities of beetle grub hemolymph. (A) Immunodetection of PrPres in ScN2a cells treated with fresh (no aging) or aged hemolymph (4 °C, 1 or 2 months).
Signals for β-actin are shown as controls for the integrity of the samples used for PrPres detection. Molecular size markers on the right indicate sizes in kDa.
(B) Immunodetection of PrPres in ScN2a cells treated with the hemolymph that had been heated at 37 °C or 70 °C for 17 h. (C) Immunodetection of PrPres in ScN2a cells
treated with the hemolymph that had been heated at 70 °C for various lengths of time. (D) Immunodetection of PrPres in ScN2a cells treated with the browned hemolymph
that had been treated with proteinase K [PK (þ)] or that had been left untreated [PK ()]. Browned hemolymph was prepared by heating hemolymph at 70 °C for 17 h.
(E) Immunodetection of PrPres in ScN2a cells treated with the retentate or ﬁltrate of browned hemolymph after ultraﬁltration through membranes with different molecular
pore sizes. Designated amounts of ﬁltrates or ﬁlled-up retentates with PBS to the original volumes were added into 10 mL of each cell culture medium.
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common structures of Maillard reaction products, are needed for
anti-prion activity against the RML prion.
3.3. Effects on PrPc expression and other prion strains
We examined the inﬂuence of anti-prion hemolymph compo-
nents on PrPc expression. We found that the browned hemolymph
samples, prepared by heating the hemolymph at 70 °C for 17 h,
modiﬁed neither the total cellular PrPc levels (Fig. 3A) nor the cell
surface PrPc levels in N2a cells (Fig. 3B). The lipid raft micro-
domain of the cell membrane, which is reportedly one of the
possible sites of PrP conversion or of interaction between PrPc and
abnormal PrP [27–31] was also examined. The cholera toxin
B-binding lipid raft levels were not modiﬁed in N2a cells treated
with the browned hemolymph samples (Fig. 3B). We examined
the anti-prion activity of the browned hemolymph samples in twoother cells infected with distinct prion strains: N167 cells infected
with 22 L prion and F3 cells infected with Fukuoka-1 prion. The
browned hemolymph samples showed no anti-prion activity in
these two cell cultures (Fig. 3C). These data suggest that the
browned hemolymph samples exert anti-prion activity in a prion-
strain dependent manner without any effects on PrPc expression.
Autophagy has been reported to regulate abnormal PrP clear-
ance [32]. Therefore, we examined whether autophagosome for-
mation is enhanced in ScN2a cells treated with browned hemo-
lymph samples. We found that the browned hemolymph samples
did not enhance autophagosome formation in these cells (Fig. 3D).
Similarly, compounds such as the tetracycline group compounds
[33] and polycationic compounds [34] turn abnormal PrP mole-
cules into less protease-resistant PrP molecules when cell lysates
containing abnormal PrP molecules are incubated with these
compounds. Therefore, we tested whether browned hemolymph
samples modify the protease sensitivity of abnormal PrP
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Fig. 2. Characterization of anti-prion components in beetle grub hemolymph. (A) Immunodetection of N(6)-carboxymethyl lysine in hemolymph that was heated at 70 °C for
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sample collection. The data from two independently collected hemolymph samples are shown. (B) Immunodetection of PrPres in ScN2a cells treated with the hemolymph
samples shown in (A). (C) Maillard reaction products of amino acids and BSA, and immunoblot data of PrPres in ScN2a cells treated with the Maillard reaction products
[Glucose (þ)]. Immunoblot data are also shown for PrPres in ScN2a cells treated with the Maillard reaction products made in the presence of aminoguanidine [Glucose (þ) &
AG (þ)]. As negative controls, immunoblot data are shown for PrPres in ScN2a cells treated with respective amino acids or BSA in the absence of glucose [Glucose ()] or
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ScN2a cells were treated by adding 0.2% (v/v) of each reaction solution to the culture medium.
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samples did not change the protease sensitivity of abnormal PrP
molecules and did not modify the stability of PrPc molecules
(Fig. 3E).4. Discussion
In the present study, we found that beetle grub hemolymph of
Trypoxylus dichotomus septentrionalis, when it is browned at 4 °C
for a month or heated for hours, inhibits abnormal PrP formation
in RML prion-infected cells. Anti-prion components in the
browned hemolymph were protease resistant and had a molecular
weight greater than 100 kDa. Treatment of the hemolymph with
aminoguanidine abolished the production of anti-prion activity,
which strongly suggests that the anti-prion components are
Maillard reaction products. Conversely, Maillard reaction products
of amino acids or BSA did not inhibit abnormal PrP formation in
RML prion-infected cells. Therefore, although the active compo-
nents of browned hemolymph need to be further evaluated,certain speciﬁc chemical structures in the hemolymph, but not the
common structures of Maillard reaction products, are likely to be
involved in inhibiting abnormal PrP formation in cells infected
with the RML prion.
Although many compounds or biological materials have been
reported to inhibit the formation of abnormal PrP in prion-infected
cells, this type of Maillard reaction product has never been re-
ported to have anti-prion activity. High-molecular-weight sub-
stances, including polycationic polymers [34], polyanionic glycans
[35], and the protein-polysaccharide complex substance PSK [17]
have potent anti-prion activity in prion-infected cells. However,
the anti-prion components in the hemolymph are different from
these high-molecular-weight substances. The anti-prion compo-
nents in the hemolymph exhibit prion-strain dependent efﬁcacy,
whereas those high-molecular-weight substances are effective not
only in RML prion-infected cells but also in cells infected with
other prion strains.
As substances similar to Maillard reaction products, melanin,
which is similarly brown-colored and of high molecular weight, is
considered because melanin is easily produced even in collected
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Fig. 3. Effects of browned hemolymph on PrPc expression and other prion strains. (A) Immunodetection of total cellular PrPc in N2a cells treated with the hemolymph that
had been heated at 70 °C for 17 h, or not heated. Cells were treated by adding 0.1% (v/v) of each reaction solution to the culture medium. (B) Flow cytometry of cell surface
PrPc (Anti-PrP) and lipid raft microdomains (Cholera-toxin B) in N2a cells treated with hemolymph that had been heated at 70 °C for 17 h, or not heated. The broken line
peaks on the left show their respective isotype controls. Cells were treated as described in (A). (C) Immunodetection of PrPres in three distinct prion-infected cell lines
treated with hemolymph that had been heated at 70 °C for 17 h, or not heated. Cells were treated as described in (A). (D) Immunodetection of autophagosome-related LC3-II
in ScN2a cells treated with hemolymph that had been heated at 70 °C for 17 h, or not heated. A trehalose-treated cell sample (TRE) is shown as a positive control. Cells were
treated as described in (A). (E) Immunodetection of PrPres and PrPc in the cell lysates treated with the browned hemolymph. ScN2a and N2a cell lysates were treated with
the browned hemolymph at designated concentrations at 37 °C for 1 h, and subsequently ScN2a cell lysates were digested with proteinase K. Then, PrPres in ScN2a cell
lysates and PrPc in N2a cell lysates were detected. Browned hemolymph was prepared as described already.
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ever, it is unlikely that melanin was produced in the hemolymph
samples we used, because they were collected in an ice cold
condition and were immediately heated at 95 °C to inactivate
phenoloxidase enzymes. In fact, the phenoloxidase enzymes in ﬂy
larvae hemolymph are reportedly inactivated by heating at 50 °C
or higher [36].
Regarding the mechanism of the action of the anti-prion
components of the browned hemolymph in prion-infected cells,
they had no effect on PrPc expression and localization; total cel-
lular and cell surface PrPc levels were not modiﬁed; and cell
membrane lipid raft microdomain levels were unchanged. In ad-
dition, the anti-prion components of the browned hemolymph did
not modify autophagosome levels, and they were active in a prion
strain-dependent manner. Considering all these together, these
results suggest that the anti-prion components of the browned
hemolymph reduce abnormal PrP levels by directly modifying
abnormal PrP formation or turnover. We previously experienced
similar results with amyloidophilic compounds such as compound
B, BSB, and styrylbenzoazole derivatives [37]. We speculate that
the prion strain-dependent efﬁcacy of these compounds isattributable to strain-speciﬁc structure, biosynthesis, or turnover
of abnormal PrP molecules. However, none of these mechanisms
of prion strain-dependency have previously been reported. The
present ﬁndings of a new class of anti-prion materials might
provide a clue to understanding the mechanisms of strain-de-
pendent anti-prion activity.
There are a few reports describing the roles of Maillard reaction
products or AGEs in prion biology or prion disease pathogenesis
[38–40]. Choi and colleagues found that one or more lysine re-
sidues and one arginine residue of abnormal PrP are speciﬁcally
modiﬁed with AGEs [38]. They suggest the Maillard reaction is
responsible for one of the post-translational modiﬁcations of ab-
normal PrP, and that it might facilitate protection of abnormal PrP
molecules against cellular degradation. Sasaki and colleagues
found that both PrP-positive granules and AGE- or AGE receptor-
immunopositive granules are colocalized in the astrocytes of hu-
man brains with prion disease, and they proposed an AGE re-
ceptor-mediated PrP degradation pathway in prion-infected brains
[39]. Taken together, these results suggest that the Maillard reac-
tion plays an important role in the biosynthesis and turnover of
abnormal PrP. Meanwhile, the ﬁndings of this study suggest that
T. Hamanaka et al. / Biochemistry and Biophysics Reports 3 (2015) 32–37 37certain Maillard reaction products inhibit abnormal PrP formation
in prion-infected cells. Thus, although their chemical structure
needs to be further elucidated, the anti-prion components of the
browned hemolymph of beetle grubs are a new tool for resolving
an enigma of prion formation and turnover. These ﬁndings may
also provide a clue to as to why some compounds are effective in a
prion strain-dependent manner.Conﬂict of interest
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